U.S. markets close in 5 hours 27 minutes
  • S&P 500

    4,239.60
    -44.14 (-1.03%)
     
  • Dow 30

    33,783.82
    -215.22 (-0.63%)
     
  • Nasdaq

    12,743.33
    -222.01 (-1.71%)
     
  • Russell 2000

    1,962.54
    -38.19 (-1.91%)
     
  • Crude Oil

    91.19
    +0.69 (+0.76%)
     
  • Gold

    1,765.80
    -5.40 (-0.30%)
     
  • Silver

    19.06
    -0.40 (-2.08%)
     
  • EUR/USD

    1.0047
    -0.0045 (-0.44%)
     
  • 10-Yr Bond

    2.9740
    +0.0940 (+3.26%)
     
  • GBP/USD

    1.1812
    -0.0121 (-1.01%)
     
  • USD/JPY

    137.0670
    +1.2050 (+0.89%)
     
  • BTC-USD

    21,449.83
    -1,975.95 (-8.43%)
     
  • CMC Crypto 200

    508.32
    -33.28 (-6.15%)
     
  • FTSE 100

    7,553.61
    +11.76 (+0.16%)
     
  • Nikkei 225

    28,930.33
    -11.81 (-0.04%)
     

Pulse Biosciences Schedules Second Quarter 2022 Financial Results Conference Call for August 10, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

HAYWARD, Calif., July 27, 2022--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the second quarter of 2022 after market close on Wednesday, August 10, 2022. Company management will host a corresponding conference call beginning at 1:30pm PT.

Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue, to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. To learn more, please visit pulsebiosciences.com.

To stay informed about the CellFX System, please visit CellFX.com and sign up for updates.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220727006009/en/

Contacts

Investors:
Pulse Biosciences
Sandra Gardiner, EVP and CFO
510.241.1077
IR@pulsebiosciences.com
or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com

Media:
Tosk Communications
Nadine D. Tosk
504.453.8344
press@pulsebiosciences.com